Radiation dermatitis in patients treated with concurrent trastuzumab emtansine (T-DM1)

Trastuzumab Emtansine (T-DM1) improves outcomes for patients with HER2+ breast cancer, and is given concurrently with radiation. We have noted increased radiation dermatitis in these patients, which may have been underreported on the KATHERINE clinical trial, and call for clinicians to remain vigila...

Descripción completa

Detalles Bibliográficos
Autores principales: Corbin, Kimberly S., Breen, William G., Strauss, Jonathan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369349/
https://www.ncbi.nlm.nih.gov/pubmed/32715108
http://dx.doi.org/10.1016/j.ctro.2020.06.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369349/
https://www.ncbi.nlm.nih.gov/pubmed/32715108
http://dx.doi.org/10.1016/j.ctro.2020.06.013

Ejemplares similares